Valo Health Receives $110 Million In Funding From Koch Disruptive Technologies To Close Series B
Valo Health Receives $110 Million In Funding From Koch Disruptive Technologies To Close Series B Valo's CEO To Provide Insights On Programs And Opal Platform At Barclays Global Healthcare Conference News provided by Share this article Share this article BOSTON, March 9, 2021 /PRNewswire/ -- Valo Health LLC (Valo), a technology company transforming the drug discovery and development process and seeking to accelerate the creation of life-changing drugs, today announced the final closing of its Series B at $300 million, including a $110 million investment from Koch Disruptive Technologies (KDT)...
Source: prnewswire.com